Cadex Genomics
Alf Merriweather has over 20 years of experience in financial leadership roles. Alf started their career in 1996 as the Vice President of Finance and CFO at Symphonix Devices Inc., a company that developed, manufactured, and commercialized implantable hearing devices. In 2001, they joined ACLARA Biosciences Inc. as the Vice President of Finance and CFO. In 2004, they moved to Monogram BioSciences, Inc. as the Senior Vice President and CFO. Alf also served as the Executive Vice President and CFO at Calypso Medical Technologies in 2010 and the SVP/CFO at Celera Corporation in 2010. Alf then joined Verinata Health, Inc. as the Chief Financial Officer in 2012 and RainDance Technologies as the Chief Financial Officer in 2013. In 2017, they became the Chief Financial Officer at Adamas Pharmaceuticals, Inc., a publicly traded biopharmaceutical company focused on neurological disease. Currently, Alf Merriweather is the Director and Chair of the Audit Committee at Cadex Genomics.
Alf Merriweather obtained a Bachelor's degree in Economics from the University of Cambridge between 1972 and 1975.
This person is not in any teams
This person is not in any offices
Cadex Genomics
Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into the therapy response. By combining proven approaches to measuring DNA with cutting-edge technology to improve accuracy and sensitivity Cadex Genomics provides unique insight into therapy response using simple blood draws.